A meta-analysis of data associating *DRD4* gene polymorphisms with schizophrenia

Feng-ling Xu
Xue Wu
Jing-jing Zhang
Bao-jie Wang
Jun Yao

Department of Forensic, Genetic and
Biology Medicine, School of Forensic
Medicine, China Medical University,
Shenyang, China

Abstract: To explore the association between *DRD4* polymorphisms and schizophrenia risk, a meta-analysis was carried out with 41 case-control articles. Specifically, we included 28 articles (5,735 cases and 5,278 controls) that pertained to the 48 bp variable number tandem repeat (VNTR) polymorphism, nine articles (1,517 cases and 1,746 controls) that corresponded to the 12 bp tandem repeat (TR), six articles (1,912 cases and 1,836 controls) that addressed the 120 bp TR, 10 articles (2,927 cases and 2,938 controls) that entailed the -521 C>T polymorphism, six articles (1,735 cases and 1,724 controls) that pertained to the -616 C>G polymorphism, and four articles (1,191 cases and 1,215 controls) that involved the -376 C>T polymorphism. Pooled analysis, subgroup analysis, and sensitivity analysis were performed, and the data were visualized by means of forest and funnel plots. Results of pooled analysis indicated that the -521 CC variant ($P_z=0.009$, odds ratio [OR] =1.218, 95% confidence interval [CI] =1.050–1.413) and genotype L/L (ie, long allele) of the 120 bp TR were risk factors of schizophrenia ($P_z=0.004$, OR =1.275, 95% CI =1.081–1.504). The 48 bp VNTR, the 12 bp TR, the -616 C>G polymorphism, and the -376 C>T polymorphism were not associated with schizophrenia. Additional research is warranted to explore the association between polymorphisms of *DRD4* and schizophrenia risk.

Keywords: *DRD4*, schizophrenia, meta-analysis, polymorphism

Introduction

Schizophrenia is a chronic, severe mental disorder with a tremendously variable clinical presentation. Results of studies in which schizophrenia occurrence was evaluated among twins or children who were adopted have shown that this disease results from an interaction of genetics and environmental factors.¹ Specifically, schizophrenia is a multigene disease with a heritability of 60%–70%.² Although the pathogenesis and etiology of schizophrenia are not understood fully,³ a large body of evidence has indicated that dopamine dysfunction is involved in the occurrence of this disease.^{4–6}

Dopamine is an endogenous neurotransmitter that primarily functions by binding to dopamine receptors, which have five types. The D4 receptor has attracted attention in the field of schizophrenia research. In postmortem brain striatum of patients with schizophrenia, the density of D4 receptor was significantly higher than in brain tissues of unaffected patients; in contrast, the density of D2 and D3 receptors remained modest.⁷ This upregulation of D4 receptor has been shown to be related to the disease rather than to pharmacological effects of treatment.⁸ The pharmacological characteristics of D4 resemble those of D2 and D3, but the affinity of D4 for clozapine is an order of magnitude higher.⁹ Hence, *DRD4* (chromosome 11p15.5) is a potential susceptibility gene for schizophrenia.¹⁰

The SZGene database is a viable resource for ascertaining the risk of schizophrenia.^{11,12} Other investigators have determined that the -521 C>T and 120 bp tandem repeat

Correspondence: Jun Yao
School of Forensic Medicine, China
Medical University, No 77 Puhe Road,
Shenbei New District, Shenyang,
110122, China
Tel +86 24 3193 9433
Email yaojun198717@163.com

(TR) polymorphisms in *DRD4* are associated with nominally significant summary odds ratios (ORs) as risk factors for schizophrenia ($P=0.003$ and 0.005 , respectively).¹¹ However, despite a great deal of research, an association between *DRD4* polymorphisms and schizophrenia risk remains debatable.

TRs in *DRD4* include a 48 bp variable number TR (VNTR), a 12 bp TR, and a 120 bp TR. The 48 bp VNTR is located in the third exon of *DRD4* and encodes a sequence of 16 amino acids in the region of the third cytoplasmic loop. Polymorphisms in the 48 bp VNTR were found to differ in the recruitment of cellular cAMP.¹³ The 12 bp TR (rs4646983) is located in the first exon of *DRD4*, which corresponds to the N terminus of the gene product. Variants of the 12 bp TR modify an N-terminal glycosylation site, which affects expression levels of the membrane protein.¹⁴ The 120 bp TR is located 1.2 kb upstream from the initiation codon, and polymorphisms at this site affect transcriptional efficiency.¹⁵ Some researchers noted that the 120 bp TR was associated with attention-deficit hyperactivity disorder (ADHD)^{16,17} and schizophrenia.¹⁸ However, Tsutsumi et al¹⁹ demonstrated that the 120 bp TR was not related to the risk of schizophrenia.

The $-521\text{ C}>\text{T}$ polymorphism (rs1800955), located in the promoter region of *DRD4*, has been shown to be associated with novelty seeking^{20,21} and schizophrenia.²² Mitsuyasu et al suggested that the -521C variant could be a risk factor for schizophrenia among female patients.²³ However, other investigators found no relationship between $-521\text{ C}>\text{T}$ and schizophrenia.²⁴ The $-616\text{ C}>\text{G}$ (rs747302) and the $-376\text{ C}>\text{T}$ (rs916455) polymorphisms are located in the promoter region of *DRD4*; these variants have not been associated conclusively with schizophrenia risk. A pooled analysis of data regarding polymorphisms in *DRD4* and schizophrenia risk is warranted.

Meta-analyses are proven tools for ascertaining associations of gene polymorphisms with disease.^{25–27} Several meta-analyses previously have addressed the potential associations between *DRD4* polymorphisms and schizophrenia risk.^{28–31} However, the authors of these studies examined just one polymorphic locus²⁸ or did not include the latest data.³¹ Herein, we describe the results of our meta-analysis of the association between *DRD4* and schizophrenia risk.

Materials and methods

Literature searches

The SZGene, PubMed, and China National Knowledge Infrastructure (CNKI) databases were searched with the keywords “schizophrenia” and “*DRD4*”. Reference lists from relevant articles also were screened to identify additional studies.

Inclusion criteria and exclusion criteria

Studies with the following features were included in the meta-analysis: 1) case–control design; 2) involved patients with schizophrenia; 3) presented relevant data for case and control groups (eg, allele/genotype frequencies, sample size, ethnicity, schizophrenia diagnostic criteria, and control group source); 4) removed duplicate sample data; and 5) published before September 1, 2017. Studies were excluded for the following reasons: 1) no control group; 2) no usable genotype frequency data (attempts were made to contact authors via email for these data); and 3) duplicate reported sample data.

Statistical analysis

A meta-analysis was carried out using Stata Version 10.0 (StataCorp LP, College Station, TX, USA). The P -value of Hardy–Weinberg equilibrium (P_{HWE}) was calculated for the control groups. ORs and 95% confidence intervals (CIs) were calculated to evaluate the strength of the associations. Under a random model,^{32,33} associations between *DRD4* and the risk of schizophrenia were analyzed. A random model took into account population differences and heterogeneity among studies.^{25,34} Pairwise differences between genotypes (AA vs aa, Aa vs aa, and AA vs Aa [A being the risk factor]) were used to determine a suitable genetic model.³⁵

The heterogeneity of the studies was determined by Cochran’s chi-square-based Q -statistic test.³⁶ The degree of heterogeneity was expressed as I^2 and was divided into low ($I^2<25\%$), medium ($I^2\sim 50\%$), and high ($I^2>75\%$) heterogeneity groups.³⁷ $I^2>50\%$ was regarded as indicating substantial heterogeneity.³⁸ Publication bias was calculated using Egger’s test and was represented as a funnel plot in which the standard error of $\log(\text{OR})$ of each study was plotted against its $\log(\text{OR})$. A sensitivity analysis was conducted to test the impact of removing each single study on the pooled result. Statistical power was calculated by means of the PS program, as described previously.^{39,40} P -values corresponding to association, heterogeneity, and publication bias tests were represented as P_z , P_h , and P_e , respectively. Statistical significance was defined as $P<0.05$ for all analyses.⁴¹

Results

Description of studies

A total of 211 English-language articles were obtained from SZGene and PubMed, and 14 Chinese-language articles were obtained from CNKI. After removing duplicate studies and those that did not meet our inclusion criteria, 41 articles were used in the meta-analysis (Figure 1). Specifically, 28 articles addressed the 48 bp VNTR,^{23,42–68} nine articles involved the 12 bp

Figure 1 Study selection process in this meta-analysis.

Abbreviations: CNKI, China National Knowledge Infrastructure; VNTR, variable number tandem repeat.

TR,^{23,43,48–50,69–72} six articles pertained to the 120 bp TR,^{18,19,65,72–74} 10 articles addressed the –521 C>T polymorphism,^{18,22–24,58,72–76} six articles referred to –616 C>G,^{18,23,72,74–76} and four articles entailed –376 C>T.^{18,23,72,75} Details of these studies are listed in Table 1. We omitted loci from our meta-analysis that were not represented in at least four articles.

Results of data analysis

No association between the 48 bp VNTR and schizophrenia risk

Allele frequencies of the 48 bp VNTR are listed in Table 2. Results of pooled analyses are summarized in Table 3, and data from subgroup analyses are depicted in Table 4. We were

Table 1 Characteristics of studies that qualified to be included in the meta-analysis

Author	Year	Country	Ethnicity	Controls source	Mean age of control group	Gender index (case)	Gender index (control)
Kaiser et al ⁴²	2000	German	Caucasian	Hospital based	43.53	0.83	0.34
Kohn et al ^{43,a}	1997	Israel	Israeli	Hospital based	–	–	–
Kohn et al ^{43,b}	1997	Israel	Israeli	Hospital based	–	–	–
Serretti et al ^{44,69}	1999, 2001	Italy	Caucasian	Hospital based	47.45	–	1.27
Hattori et al ⁴⁵	2009	Japan	East Asian	Population based	46.70	1.00	1.00
Tanaka et al ⁴⁶	1995	Japan	East Asian	Population based	45.80	0.84	0.56
Nanko et al ⁴⁷	1993	Japan	East Asian	Population based	–	–	–
Petronis et al ⁴⁸	1995	USA, Canada	Caucasian	Hospital based	–	–	–
Ohara et al ⁴⁹	1996	Japan	East Asian	Population based	34.40	0.99	1.37
Aguirre et al ⁵⁰	2007	Mexico	Indian	Population based	40.00	–	0.97
Mitsuyasu et al ^{23,c}	2007	Japan	East Asian	Hospital based	50.20	0.81	0.76
Daniels et al ⁵¹	1994	UK	Caucasian	Hospital based	49.60	0.80	0.68
Sommer et al ⁵²	1993	Minnesota	Caucasian	Population based	65.00	0.44	1.61
Rao et al ⁵³	1994	USA	Caucasian	Population based	–	–	–
Hong et al ⁵⁴	1997	Taiwan	East Asian	Hospital based	28.70	0.68	0.62
Jonsson et al ⁵⁵	1996	Sweden	Caucasian	Population based	38.70	0.573	0.73
Rinetti et al ⁵⁶	2001	Mexico	Mestizos	Hospital based	–	–	–
Fujiwara et al ⁵⁷	1997	Japan	East Asian	Population based	–	–	–
Lung et al ⁵⁸	2006	Taiwan	East Asian	Population based	45.37	–	–
Nakamura et al ⁵⁹	1995	Japan	East Asian	Population based	–	–	–
Lung et al ⁶⁰	2009	Taiwan	East Asian	Population based	–	–	–
Fresan et al ⁶¹	2007	Mexico	Caucasian	Population based	34.60	0.45	94.23
Zhang et al ⁶²	2003	China	East Asian	Population based	42.00	0.43	–
Tang et al ⁶⁸	2001	China	East Asian	Population based	33.00	0.44	0.40

(Continued)

Table 1 (Continued)

Author	Year	Country	Ethnicity	Controls source	Mean age of control group	Gender index (case)	Gender index (control)
Liang ⁶⁷	2005	China	East Asian	Population based	26.00	0.98	0.98
Zhao et al ⁶³	2005	China	East Asian	Population based	34.00	0.88	0.88
Zhao et al ⁶⁴	2006	China	East Asian	Population based	29.40	0.84	1.00
Chen et al ⁶⁵	2016	China	East Asian	Hospital based	39.19	0.81	0.89
Lu et al ⁶⁶	2003	China	East Asian	Population based	65.00	0.74	1.22
Serretti et al ⁶⁹	1999	Italy	Caucasian	Population based	—	—	—
Hong et al ⁷⁰	1998	Taiwan	East Asian	Hospital based	30.20	28.70	0.62
Catalano et al ⁷¹	1993	Italy	Caucasian	Hospital based	46.90	30.00	1.34
Nakajima et al ⁷²	2007	Japan	East Asian	Population based	47.00	46.70	1.00
Okuyama et al ²²	1999	Japan	East Asian	Population based	47.10	47.90	0.63
Mitsuyasu et al ^{75,d}	2001	Japan	East Asian	Hospital based	51.50	50.50	0.75
Jonsson et al ²⁴	2001	Sweden	Caucasian	Population based	44.80	42.60	0.80
Pai et al ⁷³	2015	India	Indian	Population based	—	—	—
Xing et al ¹⁸	2003	China	East Asian	Hospital based	41.20	41.80	—
Lai et al ⁷⁴	2010	China	East Asian	Hospital based	40.60	43.20	1.00
Zhong et al ⁷⁶	2010	China	East Asian	Population based	39.20	37.50	1.00
Tsutsumi et al ¹⁹	2011	Japan	East Asian	Hospital based	47.20	42.10	0.50

Notes: Gender index = female/male. *Ethnicity is Ashkenazi which included Jews whose origin (or whose parents' origin), was in European countries, apart from the Balkans; ^bethnicity is non-Ashkenazi which included Jews whose origin was in North Africa or Asia. ^cIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR; ^ddid not include 48 bp VNTR, 12 bp TR, and 120 bp TR.

unable to obtain specific data regarding the number of 7-repeat (7R) alleles in the 48 bp VNTR,⁴⁴ despite multiple attempts to contact the corresponding author. Thus, this study was omitted from our analysis of an association between 7R and

schizophrenia risk. When we conducted a pooled analysis of the remaining 5,316 cases and 4,677 controls, we found that 7R was not associated with schizophrenia risk ($P_z=0.349$, OR =1.071, 95% CI =0.928–1.236) under a random effects model with a

Table 2 Allele frequency of 48 bp VNTR polymorphism

Author	Allele distribution				Allele frequency			
	Cases (n)		Controls (n)		Cases (n)		Controls (n)	
	Short (≤4)	Long (≥5)	Short (≤4)	Long (≥5)	7R	Others	7R	Others
Kaiser et al ⁴²	1,006	270	1,182	322	232	1,044	282	1,222
Kohn et al ^{43,a}	—	—	—	—	22	76	52	238
Kohn et al ^{43,b}	—	—	—	—	13	85	17	101
Serretti et al ^{44,69}	709	129	990	212	—	—	—	—
Hattori et al ⁴⁵	1,066	54	1,076	60	2	1,118	6	1,130
Tanaka et al ⁴⁶	134	6	133	7	0	140	2	138
Nanko et al ⁴⁷	148	12	152	10	2	158	0	162
Petronis et al ⁴⁸	77	23	154	46	21	79	32	168
Ohara et al ⁴⁹	286	20	227	15	18	288	10	232
Aguirre et al ⁵⁰	120	72	224	114	46	146	98	240
Mitsuyasu et al ^{23,c}	406	18	447	27	1	423	3	471
Daniels et al ⁵¹	159	53	193	45	52	160	45	193
Sommer et al ⁵²	182	48	171	59	43	187	54	176
Rao et al ⁵³	39	17	31	9	17	39	8	32
Hong et al ⁵⁴	172	6	78	6	0	178	0	84
Jonsson et al ⁵⁵	187	49	124	28	42	194	23	129
Rinetti et al ⁵⁶	36	38	48	26	31	43	25	49
Fujiwara et al ⁵⁷	34	0	22	0	0	34	0	22
Lung et al ⁵⁸	1,216	44	846	10	3	1,257	0	856
Nakamura et al ⁵⁹	189	13	98	6	0	202	0	104
Lung et al ⁶⁰	1,774	54	838	8	0	1,828	0	846
Fresan et al ⁶¹	88	54	285	119	47	95	104	300
Zhang et al ⁶²	131	3	145	7	0	134	0	152
Tang et al ⁶⁸	980	40	332	10	1	1,019	0	342
Liang ⁶⁷	176	26	185	25	4	198	2	208
Zhao et al ⁶³	78	246	75	249	3	321	6	318
Zhao et al ⁶⁴	41	121	40	136	0	162	3	173
Chen et al ⁶⁵	219	49	299	37	0	268	0	336
Lu et al ⁶⁶	155	5	157	3	1	159	0	160

Notes: *Ethnicity is Ashkenazi which included Jews whose origin (or whose parents' origin), was in European countries, apart from the Balkans; ^bethnicity is non-Ashkenazi which included Jews whose origin was in North Africa or Asia. ^cIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR.

Abbreviations: 7R, 7 repeat; VNTR, variable number tandem repeat.

Table 3 Pooled associations of *DRD4* polymorphisms and schizophrenia

Loci	Genetic model	Studies (n)	Statistical model	OR	95% CI	P_z	I^2	P_h	P_e
48 bp VNTR	Allele contrast (7R and others)	27	Random	1.071	0.928–1.236	0.349	8.1	0.352	0.727
	Allele contrast (S and L)	27	Random	1.135	0.988–1.303	0.073	44.0	0.009	0.151
12 bp TR	Allele contrast	9	Random	1.037	0.885–1.215	0.659	0.0	0.931	0.584
	Homozygous codominant	9	Random	0.756	0.434–1.317	0.323	0.0	0.729	0.214
	Heterozygous codominant	9	Random	1.117	0.930–1.341	0.236	0.0	0.644	0.077
	Dominant	9	Random	1.083	0.907–1.293	0.377	0.0	0.834	0.192
	Recessive	9	Random	0.724	0.417–1.259	0.253	0.0	0.681	0.180
120 bp TR	Allele contrast	6	Random	1.189	1.040–1.358	0.011	37.1	0.159	0.701
	Homozygous codominant	6	Random	1.291	0.892–1.868	0.176	47.2	0.092	0.213
	Heterozygous codominant	6	Random	1.010	0.744–1.372	0.949	22.9	0.262	0.223
	Dominant	6	Random	1.152	0.837–1.584	0.386	34.3	0.179	0.176
	Recessive	6	Random	1.275	1.081–1.504	0.004	33.1	0.187	0.756
–521 T>C	Allele contrast	10	Random	1.113	1.024–1.209	0.011	16.2	0.294	0.628
	Homozygous codominant	10	Random	1.240	1.041–1.477	0.016	18.7	0.271	0.765
	Heterozygous codominant	10	Random	1.105	0.971–1.256	0.129	13.8	0.316	0.751
	Dominant	10	Random	1.136	1.004–1.289	0.043	19.2	0.266	0.620
	Recessive	10	Random	1.177	1.024–1.353	0.021	0.0	0.467	0.812
–616 G>C	Allele contrast	6	Random	1.103	0.991–1.226	0.071	6.7	0.373	0.604
	Homozygous codominant	6	Random	0.637	0.469–0.866	0.004	46.4	0.096	0.488
	Heterozygous codominant	6	Random	1.123	0.974–1.296	0.110	0.0	0.986	0.169
	Dominant	6	Random	1.133	0.991–1.295	0.068	0.0	0.889	0.965
	Recessive	6	Random	1.140	0.840–1.548	0.400	48.3	0.085	0.338
–376 C>T	Allele contrast	4	Random	1.124	0.940–1.344	0.198	0.0	0.707	0.200
	Homozygous codominant	4	Random	0.854	0.416–1.749	0.665	0.0	0.996	0.456
	Heterozygous codominant	4	Random	0.730	0.351–1.520	0.401	0.0	0.993	0.911
	Dominant	4	Random	0.820	0.401–1.676	0.586	0.0	0.994	0.583
	Recessive	4	Random	1.171	0.962–1.425	0.117	0.0	0.707	0.214

Notes: L, long allele; S, short allele.

Abbreviations: CI, confidence interval; OR, odds ratio; 7R, 7 repeat; TR, tandem repeat; VNTR, variable number TR.

power of 0.271 (Table 3 and Figure S1).³⁵ No association was found in subgroup analysis by ethnicity (ie, Caucasian [$P_z=0.238$, OR =1.127, 95% CI =0.924–1.375], East Asian [$P_z=0.901$, OR =0.966, 95% CI =0.560–1.667], Indian [$P_z=0.211$, OR =0.772, 95% CI =0.514–1.158], Mestizos [$P_z=0.310$, OR =1.413, 95% CI =0.725–2.754], and Israeli [$P_z=0.512$, OR =1.164, 95% CI =0.739–1.835]). Moreover, no association of 7R with the risk of schizophrenia was ascertained in subgroup analysis by source of controls. No significant heterogeneity was found in the pooled or subgroup analyses.

To incorporate data from the study of Serretti et al,⁴⁴ the 48 bp VNTR was classified into S (short allele, ≤ 4 TRs) and L (long allele, ≥ 5 TRs) groups. In the study by Kohn et al,⁴³ the 48 bp VNTR data could not be categorized into S and L groups, so this study was omitted from the analysis. The remaining data comprised 5,637 cases and 5,074 controls (Table 3 and Figure S2). Results of a pooled analysis indicated no relationship between this polymorphism and schizophrenia risk ($P_z=0.073$, OR =1.135, 95% CI =0.988–1.303) with a power of 0.909. No association was found in the subgroup analysis by source of control or by ethnicity, except for Mestizos ($P_z=0.048$, OR =1.949, 95% CI =1.007–3.77). Significant

heterogeneity was found in the pooled analysis ($P_e=0.009$, $I^2=44\%$) and in the subgroup analysis by ethnicity in the East Asian subgroup ($P_e=0.014$, $I^2=49.1\%$) and by source of control in the hospital-based subgroup ($P_e=0.016$, $I^2=59.2\%$).

No association between the 12 bp TR and schizophrenia risk

To evaluate the relationship between the 12 bp TR and the risk of schizophrenia, 1,517 cases and 1,746 controls were included (Table 5 and Figures S3–S7). Allele groups were defined as in (ie, inserted) and de (ie, deleted). In the dominant model,^{34,35} the pooled OR using a random effects model was 1.083 ($P_z=0.377$, 95% CI =0.907–1.293) with a power of 0.154 (Table 3). No association was found in subgroup analysis by ethnicity or by source of controls (Table 4). No significant heterogeneity was observed in the pooled or subgroup analyses.

Genotype L/L of the 120 bp TR might be a risk factor for schizophrenia

In a random model, a pooled analysis was conducted (1,912 cases and 1,836 controls) to evaluate the relationship between genotype L/L of the 120 bp TR and schizophrenia

Table 4 Subgroup associations of *DRD4* polymorphisms with schizophrenia

Polymorphism	Subgroup analysis	Studies (n)	OR	95% CI	P_z	P_h	I^2
48 bp VNTR (7R and others)	Overall	22	1.095	0.953–1.259	0.349	0.352	8.1
	Ethnicity						
	Caucasian	7	1.127	0.924–1.375	0.238	0.195	30.6
	East Asian	11	0.966	0.560–1.667	0.901	0.413	3.1
	Indian	1	0.772	0.514–1.158	0.211	–	–
	Mestizos	1	1.413	0.725–2.754	0.310	–	–
	Israeli	2	1.164	0.739–1.835	0.512	0.441	0.0
	Source of controls						
	Population based	15	1.031	0.796–1.336	0.816	0.242	18.9
	Hospital based	7	1.070	0.917–1.248	0.393	0.490	0.0
48 bp VNTR (S and L)	Overall	26	1.147	1.003–1.312	0.073	0.009	44.0
	Ethnicity						
	Caucasian	8	1.037	0.882–1.219	0.662	0.173	32.0
	East Asian	16	1.165	0.919–1.475	0.206	0.014	49.1
	Indian	1	1.179	0.815–1.705	0.382	–	–
	Mestizos	1	1.949	1.007–3.770	0.048	–	–
	Israeli						
	Source of controls						
	Population based	18	1.165	0.977–1.390	0.089	0.069	35.4
	Hospital based	8	1.091	0.862–1.381	0.468	0.016	59.2
12 bp TR	Overall	10	1.083	0.907–1.293	0.377	0.834	0.0
	Ethnicity						
	Indian	1	0.927	0.533–1.612	0.788	–	–
	Caucasian	3	0.787	0.509–1.218	0.283	0.611	0.0
	East Asian	4	1.178	0.949–1.462	0.137	0.910	0.0
	Israeli	2	1.312	0.642–2.679	0.456	0.610	0.0
	Source of controls						
	Population based	4	1.133	0.908–1.413	0.270	0.710	0.0
	Hospital based	6	1.012	0.706–1.450	0.949	0.272	21.5
	Overall	6	1.275	1.081–1.504	0.004	0.187	33.1
120 bp TR	Ethnicity						
	East Asian	5	1.317	1.108–1.565	0.002	0.196	33.9
	Indian	1	0.979	0.629–1.524	0.924	–	–
	Source of controls						
	Population based	2	1.102	0.892–1.360	0.368	0.551	0.0
	Hospital based	4	1.319	1.134–1.708	0.002	0.225	31.2
	Overall	10	1.177	1.024–1.353	0.021	0.467	0.0
	Ethnicity						
	Caucasian	1	1.136	0.670–1.925	0.636	–	–
	East Asian	8	1.218	1.050–1.413	0.009	0.571	0.0
–521 T>C	Indian	1	0.715	0.395–1.293	0.267		
	Source of controls						
	Population based	6	1.188	0.972–1.451	0.092	0.258	23.5
	Hospital based	4	1.143	0.901–1.450	0.270	0.561	0.0
	Overall	6	1.133	0.991–1.295	0.068	0.889	0.0
	Source of controls						
	Population based	2	1.117	0.915–1.364	0.275	0.966	0.0
	Hospital based	4	1.146	0.956–1.317	0.140	0.645	0.0
	Overall	4	1.171	0.962–1.425	0.117	0.707	0.0
	Source of controls						
–616 G>C	Population based	1	1.079	0.805–1.447	0.611	–	–
	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0
	Source of controls						
	Population based	1	1.079	0.805–1.447	0.611	–	–
	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0
	Source of controls						
	Population based	1	1.079	0.805–1.447	0.611	–	–
	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0
	Source of controls						
	Population based	1	1.079	0.805–1.447	0.611	–	–
–376 C>T	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0
	Source of controls						
	Population based	1	1.079	0.805–1.447	0.611	–	–
	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0
	Source of controls						
	Population based	1	1.079	0.805–1.447	0.611	–	–
	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0
	Source of controls						
	Population based	1	1.079	0.805–1.447	0.611	–	–
	Hospital based	3	1.252	0.960–1.632	0.117	0.653	0.0

Notes: L, long allele; S, short allele.

Abbreviations: CI, confidence interval; OR, odds ratio; 7R, 7 repeat; TR, tandem repeat; VNTR, variable number TR.

risk (Table 6 and Figures S8–S12). In the recessive model,^{34,35} genotype L/L was found to be a potential risk factor for schizophrenia ($P_z=0.004$, OR=1.275, 95% CI=1.081–1.504) with a power of 0.959 (Table 3). Findings from subgroup analysis indicated significant associations in East Asian

($P_z=0.002$, OR =1.317, 95% CI =1.108–1.565) and hospital-based subgroups ($P_z=0.002$, OR =1.319, 95% CI =1.134–1.708) (Table 4). No association was found for the other subgroups, and no significant heterogeneity was ascertained in the pooled or subgroup analyses.

The –521 CC variant might be a risk factor for schizophrenia

Pooled and subgroup analyses were performed in a random model with 2,927 cases and 2,938 controls (Table 7 and Figures S13–S17). In the recessive model, –521 CC was found to be a potential risk factor for schizophrenia in the

pooled analysis ($P_z=0.021$, OR=1.177, 95% CI=1.024–1.353) with a power of 0.656 (Table 3). In subgroup analyses by ethnicity and source of controls, the association was only detected in the East Asian subgroup ($P_z=0.009$, OR=1.218, 95% CI=1.050–1.413) (Table 4). No significant heterogeneity was noted in the pooled or subgroup analyses.

Table 5 Genotype distribution and allele frequency of 12 bp TR

Author	Genotype distribution						<i>P</i> _{HWE}	Allele frequency			
	Cases, n			Controls, n				Case (%)		Controls (%)	
	in/in	in/de	de/de	in/in	in/de	de/de		in	de	in	de
Petronis et al ⁴⁸	43	6	1	80	20	0	0.267	92.00	8.00	90.00	10.00
Ohara et al ⁴⁹	144	9	0	116	5	0	0.816	97.06	2.94	97.93	2.07
Serretti et al ^{44,69}	184	28	0	225	37	1	0.689	0.93	0.07	0.93	0.07
Aguirre et al ⁵⁰	48	34	1	75	55	4	0.102	78.31	21.69	76.49	23.51
Mitsuyasu et al ^{23,a}	136	56	5	176	53	10	0.027	83.20	16.70	84.70	15.30
Kohn et al ^{43,b}	40	9	0	126	19	0	0.311	94.00	6.00	91.00	9.00
Kohn et al ^{43,c}	44	4	1	53	6	0	0.416	94.00	6.00	94.00	6.00
Hong et al ⁵⁴	68	10	2	35	7	0	0.556	91.25	8.75	91.70	8.30
Catalano et al ⁷¹	76	3	0	69	6	0	0.718	98.10	1.90	96.00	4.00
Nakajima et al ⁷²	413	140	12	431	119	18	0.008	85.50	14.50	86.50	13.50

Notes: P_{HWE} P -value of Hardy–Weinberg equilibrium. ^aIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR. ^bEthnicity is Ashkenazi which included Jews whose origin (or whose parents' origin), was in European countries, apart from the Balkans; ^cethnicity is non-Ashkenazi which included Jews whose origin was in North Africa or Asia.

Abbreviations: de, deleted; in, inserted; TR, tandem repeat.

Table 6 Genotype distribution and allele frequency of 120 bp TR

Author	Genotype distribution						P _{HWE}	Allele frequency			
	Cases, n			Controls, n				Cases (%)		Controls (%)	
	S/S	S/L	L/L	S/S	S/L	L/L		S	L	S	L
Mitsuyasu et al ^{123,a}	10	75	129	13	87	139	0.898	77.80	22.20	76.40	23.60
Pai et al ⁷³	23	77	87	11	61	64	0.501	32.90	67.10	30.50	69.50
Xing et al ¹⁸	20	77	113	28	98	80	0.816	27.90	72.10	37.40	62.60
Nakajima et al ⁷²	24	183	362	33	192	345	0.363	20.00	80.00	23.00	78.00
Tsutsumi et al ¹⁹	24	138	248	16	158	211	0.041	22.68	77.32	24.68	75.32
Lai et al ⁷⁴	28	161	133	40	166	94	0.013	33.70	66.30	41.00	59.00

Notes: L, long allele; P_{HWE} P -value of Hardy–Weinberg equilibrium; S, short allele. ^aIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR.

Abbreviation: TR, tandem repeat.

Table 7 Genotype distribution and allele frequency of –521 C>T

Author	Genotype distribution						P _{HWE}	Allele frequency			
	Cases, n			Controls, n				Cases (%)		Controls (%)	
	CC	CT	TT	CC	CT	TT		C	T	C	T
Okuyama et al ²²	58	125	69	38	142	89	0.119	48.00	52.00	41.00	59.00
Mitsuyasu et al ^{23,a}	33	106	67	31	115	93	0.623	41.75	58.25	37.05	62.95
Mitsuyasu et al ^{75,b}	25	122	61	25	110	75	0.109	41.30	58.70	38.10	61.90
Lung et al ⁵⁸	80	320	230	48	204	173	0.294	38.10	61.90	35.30	64.70
Jonsson et al ²⁴	23	74	35	60	205	118	0.061	45.50	54.50	42.00	58.00
Pai et al ⁷³	27	92	62	26	77	29	0.055	40.30	59.70	48.90	51.10
Xing et al ¹⁸	37	103	70	25	111	70	0.059	42.10	57.90	39.10	60.90
Nakajima et al ⁷²	106	270	190	89	285	195	0.368	43.00	58.00	41.00	59.00
Lai et al ⁷⁴	87	115	120	81	95	124	–	44.88	55.12	42.83	57.17
Zhong et al ⁷⁶	62	78	60	53	64	83	–	45.91	54.09	42.50	57.50

Notes: P_{HWE} P -value of Hardy–Weinberg equilibrium. ^aIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR; ^bdid not include 48 bp VNTR, 12 bp TR, and 120 bp TR.

Abbreviation: TR, tandem repeat.

Table 8 Genotype distribution and allele frequency of –616 C>G

Author	Genotype distribution						P _{HWE}	Allele frequency			
	Cases, n			Controls, n				Cases (%)		Controls (%)	
	GG	GC	CC	GG	GC	CC		G	C	G	C
Mitsuyasu et al ^{23,a}	102	89	19	112	98	30	0.243	69.80	30.20	67.10	32.90
Mitsuyasu et al ^{75,b}	89	89	30	100	85	25	0.296	64.20	35.80	67.90	32.10
Xing et al ¹⁸	83	100	27	91	102	13	0.025	63.30	36.70	68.90	31.10
Nakajima et al ⁷²	267	248	49	285	224	59	0.134	69.00	31.00	69.50	29.50
Lai et al ⁷⁴	161	113	48	166	102	32	0.009	67.55	32.45	72.33	27.67
Zhong et al ⁷⁶	112	77	31	107	68	25	0.010	68.41	31.59	70.50	29.50

Notes: P_{HWE} , P -value of Hardy–Weinberg equilibrium. ^aIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR; ^bdid not include 48 bp VNTR, 12 bp TR, and 120 bp TR.

Abbreviation: TR, tandem repeat.

Table 9 Genotype distribution and allele frequency of –376 C>T

Author	Genotype distribution						P _{HWE}	Allele frequency			
	Cases, n			Controls, n				Cases (%)		Controls (%)	
	CC	CT	TT	CC	CT	TT		C	T	C	T
Mitsuyasu et al ^{23,a}	177	34	1	193	43	1	0.39	91.50	8.50	90.45	9.45
Mitsuyasu et al ^{75,b}	179	28	1	168	41	1	0.367	92.80	0.72	89.80	1.02
Xing et al ⁷⁴	137	66	7	127	74	5	0.126	81.00	19.00	79.60	20.40
Nakajima et al ⁷²	453	100	8	447	108	7	0.869	90.00	10.00	89.50	10.50

Notes: P_{HWE} , P -value of Hardy–Weinberg equilibrium. ^aIncluded 48 bp VNTR, 12 bp TR, and 120 bp TR; ^bdid not include 48 bp VNTR, 12 bp TR, and 120 bp TR.

Abbreviation: TR, tandem repeat.

No association between –616 C>G and the risk of schizophrenia

In a random model, pooled (Table 3) and subgroup (Table 4) analyses were performed with 1,735 cases and 1,724 controls (Table 8 and [Figures S18–S22](#)). Using the dominant model, results of the pooled analysis indicated a lack of an association between –616 C>G and schizophrenia risk ($P_z=0.068$, OR=1.133, 95% CI=0.991–1.295) with a power of 0.45. All cases and controls in this analysis corresponded to the East Asian subgroup. Findings from a subgroup analysis of source of controls showed no association. There was no significant heterogeneity in the pooled or subgroup analyses.

No association of the –376 C>T variant with schizophrenia

We assessed the relationship between the –376 C>T polymorphism and schizophrenia risk in pooled and subgroup analyses of 1,191 cases and 1,215 controls in a random model (Tables 3, 4, and 9 and [Figures S23–S27](#)). In the recessive model, –376 C>T was not associated with the risk of schizophrenia in a pooled analysis ($P_z=0.117$, OR=1.171, 95% CI=0.962–1.425) with a power of 0.357 (Table 3). No association was detected in subgroup analyses by ethnicity or source of controls (Table 4). No significant heterogeneity was ascertained in the pooled or subgroup analyses.

Sensitivity analysis

The results of sensitivity analyses showed that the combined ORs did not change significantly for meta-analyses in which

each study was omitted singly. Thus, the results were considered stable and reasonable.

Publication bias

Potential publication bias was found in funnel plots in which the standard error of log(OR) of each study was plotted against its log(OR). No evidence of publication bias was found in pooled analyses (Figures 2–8).

Discussion

Results of other studies have associated the 7R polymorphism with ADHD in a meta-analysis⁷⁷ and with increased brain

Figure 2 Funnel plot analysis for the detection of publication bias in the association between the 48 bp VNTR (7R vs others) and schizophrenia.

Abbreviations: OR, odds ratio; 7R, 7 repeat; VNTR, variable number tandem repeat.

Figure 3 Funnel plot analysis for the detection of publication bias in the association between 48 bp VNTR (L vs S) and schizophrenia.

Notes: L, long allele; S, short allele.

Abbreviations: OR, odds ratio; VNTR, variable number tandem repeat.

Figure 6 Funnel plot analysis for the detection of publication bias in the association between -521 C>T and schizophrenia.

Abbreviation: OR, odds ratio.

Figure 4 Funnel plot analysis for the detection of publication bias in the association between 12 bp TR and schizophrenia.

Abbreviations: OR, odds ratio; TR, tandem repeat.

Figure 7 Funnel plot analysis for the detection of publication bias in the association between -616 C>G and schizophrenia.

Abbreviation: OR, odds ratio.

Figure 5 Funnel plot analysis for the detection of publication bias in the association between 120 bp TR and schizophrenia.

Abbreviations: OR, odds ratio; TR, tandem repeat.

Figure 8 Funnel plot analysis for the detection of publication bias in the association between -376 C>T and schizophrenia.

Abbreviation: OR, odds ratio.

activity to unpleasant stimuli.⁷⁸ We sought to determine whether 7R was also associated with schizophrenia risk. Findings of our pooled and subgroup analyses indicated that 7R was not associated with the risk of schizophrenia. Similarly, we found that the 48 bp VNTR (classified into L and S groups) was not associated with schizophrenia risk in most of our pooled and subgroup analyses, which is consistent with previously published meta-analyses.^{29,30} Only in the Mestizos subgroup, an association was detected. Our literature search yielded one article addressing Mestizos patients, and this article had an insufficient sample size to verify this association. Hence, the utility of the 48 bp VNTR as a means to assess schizophrenia risk in the Mestizo population warrants additional investigation. Lung et al²⁸ demonstrated an association between the 48-bp VNTR and schizophrenia risk but noted that sample bias might have led to a false-positive result.²⁹

We determined that the L/L genotype of the 120 bp TR and the -521 CC variant might be risk factors for schizophrenia among East Asians; this relationship was not found in other populations. This discrepancy between East Asians and other populations might have resulted from the small sample sizes of the other ethnicity subgroups, the distinct genetic backgrounds, or different demographic or lifestyle factors within the subgroups. The statistical power for the pooled analysis of the 12 bp TR, the -616 C>G polymorphism, and the -376 C>T variant was low. Therefore, these results will need to be validated further. In a study of linkage disequilibrium (LD) of *DRD4* that included 17 polymorphisms,²³ the authors found no LD between -521 T>C and 120 bp TR ($r^2=0.00$). For all pairs of -616 C>G, -376 C>T, 12 bp TR, and 48 bp VNTR, no significant LD was observed.

Multiple meta-analyses have been conducted to date on the association between *DRD4* and schizophrenia. The current meta-analysis included some new studies, involved a large sample size, and had high statistical power. We addressed six loci in *DRD4*; no other meta-analysis involving four of these loci (12 bp TR, 120 bp TR, -616 C>G, and -376 C>T) has been carried out. Moreover, we conducted subgroup analysis by ethnicity and by source of controls and included data both from SZGene and the CNKI databases.

The results described herein should be interpreted with caution. The present study was limited by a lack of exact allele/genotype frequencies for some of the included articles, despite our efforts to acquire this information from the corresponding authors. Therefore, these articles were omitted from the meta-analysis. Second, controls in some of the articles did not conform to Hardy–Weinberg equilibrium

because of sample bias. Third, case–control studies were included in this meta-analysis, but family-based studies were not.⁷⁷ The ability to exploit cosegregation of variants with disease within families helps distinguish causal from noncausal factors. Family-based studies are more powerful to detect risk factors of diseases.⁷⁹ Moreover, we did not address possible interactions between the six loci and epigenetic factors. An association between *DRD4* and schizophrenia risk was detected based on case–control studies rather than on functional ones. Our results will need to be validated on a functional level.

Conclusion

The -521 CC variant and the L/L genotype of the 120-bp TR might be risk factors for schizophrenia. No association with schizophrenia was detected for the 48 bp VNTR, the 12 bp TR, -616 C>G, or -376 C>T. Our results may provide an informative reference for subsequent genome-wide association studies.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No 81601653) and the Doctoral Research Start Foundation of Liaoning Province (201601115) (both to Dr Jun Yao). The article was edited by native English-speaking experts of BioMed Proofreading, LLC.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Sullivan PF. The genetics of schizophrenia. *PLoS Med*. 2005;2(7):e212.
2. Tsuang MT, Stone WS, Faraone SV. Schizophrenia: a review of genetic studies. *Harv Rev Psychiatry*. 1999;7(4):185–207.
3. Wray NR, Visscher PM. Narrowing the boundaries of the genetic architecture of schizophrenia. *Schizophr Bull*. 2010;36(1):14–23.
4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology*. 1988;1(3):179–186.
5. Sit SY. Dopamine agonists in the treatment of Parkinson's disease past, present and future. *Curr Pharm Des*. 2000;6(12):1211–1248.
6. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. *J Psychopharmacol*. 2015;29(2):97–115.
7. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. *Nature*. 1993;365(6445):441–445.
8. Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. *Brain Res*. 1995;681(1–2):109–116.
9. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. *Nature*. 1991;350(6319):610–614.
10. Macciardi F, Petronis A, Van Tol HH, et al. Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred. *Arch Gen Psychiatry*. 1994;51(4):288–293.

11. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. *Nat Genet.* 2008;40(7):827–834.
12. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. *Schizophr Bull.* 2008;34(5):806–812.
13. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. *J Neurochem.* 1995;65(3):1157–1165.
14. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. *Annu Rev Biochem.* 1985;54:631–664.
15. D'Souza UM, Russ C, Tahir E, et al. Functional effects of a tandem duplication polymorphism in the 5' flanking region of the DRD4 gene. *Biol Psychiatry.* 2004;56(9):691–697.
16. McCracken JT, Smalley SL, McGough JJ, et al. Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). *Mol Psychiatry.* 2000;5(5):531–536.
17. Mill J, Fisher N, Curran S, Richards S, Taylor E, Asherson P. Polymorphisms in the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. *Neuroreport.* 2003;14(11):1463–1466.
18. Xing QH, Wu SN, Lin ZG, et al. Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene in schizophrenia. *Schizophr Res.* 2003;65(1):9–14.
19. Tsutsumi A, Glatt SJ, Kanazawa T, et al. The genetic validation of heterogeneity in schizophrenia. *Behav Brain Funct.* 2011;7:43.
20. Okuyama Y, Ishiguro H, Nankai M, Shibuya H, Watanabe A, Arinami T. Identification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality trait. *Mol Psychiatry.* 2000;5(1):64–69.
21. Ronai Z, Szekely A, Nemoda Z, et al. Association between Novelty Seeking and the -521 C/T polymorphism in the promoter region of the DRD4 gene. *Mol Psychiatry.* 2001;6(1):35–38.
22. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. *Biochem Biophys Res Commun.* 1999;258(2):292–295.
23. Mitsuyasu H, Kawasaki H, Ninomiya H, et al. Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients. *J Psychiatr Res.* 2007;41(9):763–775.
24. Jonsson EG, Ivo R, Forslund K, et al. No association between a promoter dopamine D(4) receptor gene variant and schizophrenia. *Am J Med Genet.* 2001;105(6):525–528.
25. Munafò MR, Flint J. Meta-analysis of genetic association studies. *Trends Genet.* 2004;20(9):439–444.
26. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol Community Health.* 2013;67(11):974–978.
27. Lanara Z, Giannopoulou E, Fullen M, et al. Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection. *Hum Genomics.* 2013;7(1):14.
28. Lung FW, Tzeng DS, Shu BC. Ethnic heterogeneity in allele variation in the DRD4 gene in schizophrenia. *Schizophr Res.* 2002;57(2–3):239–245.
29. Glatt SJ, Faraone SV, Tsuang MT. Schizophrenia is not associated with DRD4 48-base-pair-repeat length or individual alleles: results of a meta-analysis. *Biol Psychiatry.* 2003;54(6):629–635.
30. Jonsson EG, Sedvall GC, Nothen MM, Cichon S. Dopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analyses. *Schizophr Res.* 2003;61(1):111–119.
31. Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. *Schizophr Res.* 2008;104(1–3):96–107.
32. Terracciano A, Sutin AR, An Y, et al. Personality and risk of Alzheimer's disease: new data and meta-analysis. *Alzheimers Dement.* 2014;10(2):179–186.
33. Palmer SC, Gardner S, Tonelli M, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. *Am J Kidney Dis.* 2016;68(5):691–702.
34. Pan Y, Yao J, Wang B. Association of dopamine D1 receptor gene polymorphism with schizophrenia: a meta-analysis. *Neuropsychiatr Dis Treat.* 2014;10:1133–1139.
35. Thakakian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. *Stat Med.* 2005;24(9):1291–1306.
36. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. *Genet Epidemiol.* 2005;28(2):123–137.
37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327(7414):557–560.
38. Naing C, Reid SA, Aung K. Comparing antibiotic treatment for leptospirosis using network meta-analysis: a tutorial. *BMC Infect Dis.* 2017;17(1):29.
39. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. *Control Clin Trials.* 1998;19(6):589–601.
40. Xu FL, Ding M, Yao J, et al. Association between mitochondrial DNA variations and schizophrenia in the northern Chinese Han population. *PLoS One.* 2017;12(8):e0182769.
41. Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. *BMJ.* 2015;351:h4718.
42. Kaiser R, Konneker M, Henneken M, et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. *Mol Psychiatry.* 2000;5(4):418–424.
43. Kohn Y, Ebstein RP, Heresco-Levy U, et al. Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects. *Eur Neuropsychopharmacol.* 1997;7(1):39–43.
44. Serretti A, Lilli R, Lorenzi C, Lattuada E, Smeraldi E. DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. *Am J Med Genet.* 2001;105(3):283–290.
45. Hattori E, Nakajima M, Yamada K, et al. Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia. *Eur J Hum Genet.* 2009;17(6):793–801.
46. Tanaka T, Igarashi S, Onodera O, et al. Lack of association between dopamine D4 receptor gene and schizophrenia. *Am J Med Genet.* 1995;60(6):580–582.
47. Nanko S, Hattori M, Ikeda K, Sasaki T, Kazamatsuri H, Kuwata S. Dopamine D4 receptor polymorphism and schizophrenia. *Lancet.* 1993;341(8846):689–690.
48. Petronis A, Macciardi F, Athanassiades A, et al. Association study between the dopamine D4 receptor gene and schizophrenia. *Am J Med Genet.* 1995;60(5):452–455.
49. Ohara K, Nakamura Y, Xie DW, et al. Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia. *Biol Psychiatry.* 1996;40(12):1209–1217.
50. Aguirre AJ, Apiquian R, Fresan A, Cruz-Fuentes C. Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. *Psychiatry Res.* 2007;153(3):209–215.
51. Daniels J, Williams J, Mant R, Asherson P, McGuffin P, Owen MJ. Repeat length variation in the dopamine D4 receptor gene shows no evidence of association with schizophrenia. *Am J Med Genet.* 1994;54(3):256–258.
52. Sommer SS, Lind TJ, Heston LL, Sobell JL. Dopamine D4 receptor variants in unrelated schizophrenic cases and controls. *Am J Med Genet.* 1993;48(2):90–93.
53. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. *Arch Gen Psychiatry.* 1994;51(11):912–917.
54. Hong CJ, Lee YL, Sim CB, Hwu HG. Dopamine D4 receptor variants in Chinese sporadic and familial schizophrenics. *Am J Med Genet.* 1997;74(4):412–415.
55. Jonsson E, Brene S, Geijer T, et al. A search for association between schizophrenia and dopamine-related alleles. *Eur Arch Psychiatry Clin Neurosci.* 1996;246(6):297–304.

56. Rinetti G, Camarena B, Cruz C, et al. Dopamine D4 receptor (DRD4) gene polymorphism in the first psychotic episode. *Arch Med Res*. 2001; 32(1):35–38.
57. Fujiwara Y, Yamaguchi K, Tanaka Y, et al. Polymorphism of dopamine receptors and transporter genes in neuropsychiatric diseases. *Eur Neurol*. 1997;38 Suppl 1:6–10.
58. Lung FW, Chen N, Shu BC. Dopamine D4 receptor gene and the -521C>T polymorphism of the upstream region of the dopamine D4 receptor gene in schizophrenia. *Psychiatr Genet*. 2006;16(4):139–143.
59. Nakamura M, Inoue A, Hemmi H, Suzuki J. Positive associations between dopamine D4 receptor polymorphism and schizophrenia. *Eur Neuropsychopharmacol*. 2006;6(Suppl 3):136–136.
60. Lung FW, Shu BC, Kao WT, Chen CN, Ku YC, Tzeng DS. Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study. *BMC Med Genet*. 2009;10:147.
61. Fresan A, Camarena B, Apiquian R, Aguilar A, Urraca N, Nicolini H. Association study of MAO-A and DRD4 genes in schizophrenic patients with aggressive behavior. *Neuropsychobiology*. 2007;55(3–4): 171–175.
62. Zhang M, Jianjun Y, Yongchao Q, Xia Z, Yiping H, et al. Association of schizophrenia with six candidate functional genes. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. 2003;20(1):69–71.
63. Zhao A, Zhimin X, Jindong C, Xiaogang C, Zhening L, et al. Association analysis of dopamine D4 receptor gene with quality traits and quantitative traits of schizophrenia. *Chin J Psychiatry*. 2005;38(1):3–6.
64. Zhao A, Jinuo Z, Jia F, Yuhu Z. Association analysis of dopamine D4 gene and serotonin 2A receptor gene in schizophrenia. *Chin J Behav Med Brain Sci*. 2006;15(10):865–867.
65. Chen X, Jianhua C, Weidong J. Association of DRD4 exon III gene polymorphism with attack behavior and psychiatric symptoms in patients with schizophrenia. *Chin J Clin Med*. 2016; 10(18):2692–2695.
66. Lu Z, Dongxiang W, Yiping Q, Fei L, Ye Z, et al. Association analysis of dopamine DR4 receptor gene and apolipoprotein E gene in schizophrenia. *Chin J Psychiatry*. 2003;36(1):17–20.
67. Liang KW. [The association of DA2, DA3, and DA4 receptor gene polymorphology with schizophrenia also in medical jurisprudence and human genetics studies] [doctor's thesis]. Shenyang: China Medical University; 2005. Chinese.
68. Tang Y, Zhuoji C, Rulun Z, Chaofeng Z. Association analysis of schizophrenia and dopamine D4 receptor gene polymorphism. *Chin J Med Sci*. 2001;81(16):995–998.
69. Serretti A, Lilli R, Di Bella D, et al. Dopamine receptor D4 gene is not associated with major psychoses. *Am J Med Genet*. 1999;88(5): 486–491.
70. Hong CJ, Chiu HJ, Chang YS, Sim CB. Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. *Biol Psychiatry*. 1998;43(6):432–435.
71. Catalano M, Nobile M, Novelli E, Nothen MM, Smeraldi E. Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. *Biol Psychiatry*. 1993;34(7):459–464.
72. Nakajima M, Hattori E, Yamada K, et al. Association and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenics. *J Hum Genet*. 2007;52(1):86–91.
73. Pai P, Arathil P, Kotambail A, et al. Association of GRIN1, ABCB1, and DRD4 genes and response to antipsychotic drug treatment in schizophrenia. *Psychiatr Genet*. 2015;25(3):135–136.
74. Lai JH, Zhu YS, Huo ZH, et al. Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction. *Brain Res*. 2010;1359:227–232.
75. Mitsuyasu H, Hirata N, Sakai Y, et al. Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene (DRD4) with schizophrenia and personality traits. *J Hum Genet*. 2001;46(1):26–31.
76. Zhong H, Liang P, Yongsheng Z, Jie P, Zhenghao H. Association of dopamine D4 receptor gene promoter region polymorphism with schizophrenia. *Adv Mod Biomed*. 2010;10(11):3231–3234.
77. Smith TF. Meta-analysis of the heterogeneity in association of DRD4 7-repeat allele and AD/HD: stronger association with AD/HD combined type. *Am J Med Genet B Neuropsychiatr Genet*. 2010;153B(6): 1189–1199.
78. Gehricke JG, Swanson JM, Duong S, et al. Increased brain activity to unpleasant stimuli in individuals with the 7R allele of the DRD4 gene. *Psychiatry Res*. 2015;231(1):58–63.
79. Yang Z, Thomas DC. Two-stage family-based designs for sequencing studies. *BMC Proc*. 2014;8(Suppl 1):S32.

Neuropsychiatric Disease and Treatment

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS,

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

Dovepress

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.